An Empirical Study On Ipo Underpricing Of Pharmaceutical Manufacturing

Qian Hong-Yu,Guo Ying-Nan,Li Xiao-Shuang,Zhuang Si-Yong
2016-01-01
Abstract:For decades, China's pharmaceutical industry has shown a strong growth momentum, which growth is more than 19%. In the article we use four aspects to explain IPO underpricing, and select IPO initial return ratio as an indicator to measure IPO underpricing. We use IPO initial return as the dependent variable and 11 factors as independent variables to affect IPO underpricing. We find that the IPO underpricing ratio of Chinese pharmaceutical manufacturing companies is very high and, the average rate can be as high as 91.67%. Meanwhile, time gap, lottery ratio, natural logarithm of the total funds raised, the issuing cost per share, turnover rate and market return could effectively explain IPO underpricing. To some extent, underwriter reputation, price volatility, price-earnings ratio, net profit growth rate and operating income growth rate are not found to affect in the pharmaceutical market.
What problem does this paper attempt to address?